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LIST OF ABBREVIATIONS 
AIP: autoimmune pancreatitis 
CA19-9: carcinoma antigen 19-9 
CBD: common bile duct  
CP: chronic pancreatitis 
CT: computed tomography 
EUS: endoscopic ultrasound 
EUS-FNA: endoscopic ultrasound-guided fine needle aspiration 
ERCP: endoscopic retrograde cholangiopancreatography 
ESGE: European Society of Gastrointestinal Endoscopy 
IPAS: intrapancreatic accessory spleen 
IPM: intrapancreatic metastasis 
IPMN: intraductal papillary mucinous neoplasm 
GI: gastrointestinal 
HCC: hepatocellular carcinoma 
HE: hematoxylin-eosin 
LN: lymph node 
MCAC: mucinous cystadenocarcinoma 
MCN: mucinous cystic neoplasm 
MPD: main pancreatic duct 
MRI: magnetic resonance imaging 
NET: neuroendocrine tumors 
NPV: negative predictive value  
PDAC: pancreatic ductal adenocarcinoma 
PS: plastic stents 
PSCC: pancreatic squamous cell carcinoma 
ROSE: rapid on-site evaluation 
SEMS: self-expandable metal stent 
SP: slow-pull technique 
PPV: positive predictive value 
SR: strain ratio 
SS: standard suction technique 







Upper gastrointestinal (GI) and pancreatobiliary cancers, including those of the esophagus, 
stomach, extrahepatic biliary tracts, and pancreas, are one of the leading causes of cancer-related 
morbidity and mortality worldwide. Endoscopy is the gold standard for the diagnosis of these 
malignancies; however, conventional gastroscopy is suitable only for examination of the mucosal 
surface of GI tract, and it is often inadequate for detecting small lesions. In recent decades, there have 
been rapid advances in the GI endoscopic technique which led to the emergence of new diagnostic and 
therapeutic modalities such as endoscopic retrograde cholangiopancreatography (ERCP) and 
endoscopic ultrasound (EUS). ERCP is an invasive procedure that provides radiological visualization 
of the detailed structure and the pathological changes of the biliary tree and pancreatic ducts by injection 
of contrast agent into the common bile duct (CBD) and the main pancreatic duct (MPD). EUS is a 
minimally invasive procedure combining endoscopy with ultrasound, which allows ultrasound 
transducer to get close to the organs inside the body. As a result, higher ultrasound frequency is 
applicable, which improves the spatial resolution at the expense of depth of ultrasound waves’ 
penetration. Although its role is still inevitable in the staging of esophageal, stomach, pancreatic and 
rectal tumors, in the recent years its therapeutic significance has come to the fore. At the same time, 
ERCP has also transformed from a diagnostic method to an almost exclusively therapeutic procedure. 
Endoscopic interventions represent a less invasive therapeutic option for patients compared to surgery 
because it is less burdensome, does not need general anesthesia and could reduce hospital time. It is 
especially favorable for elderly and for patients in poor clinical condition; furthermore, it does not 
require the delay of initiation of oncologic treatment as opposed to surgery. Although international 
guidelines attempt to precisely define the indication of these innovative advanced endoscopic 
modalities, there are still several open questions.  
Despite the increasing use of EUS-guided fine needle aspiration (EUS-FNA), there are no 
evidence-based recommendations about the detailed technique and processing of smears, therefore, they 
vary substantially across medical centers. The optimal sampling technique is expected to produce 
samples of satisfactory quality with high cellularity and low blood contamination. The high number of 
smears is one of major limitations of EUS-FNA, because it increases costs and the length of pathological 
evaluation. These quality features are influenced by the needle and suction characteristics, as well as by 
vascularity and stiffness of the tumor. The suction force for sampling can be generated by multiple 
different ways. The slow pull out of stylet during the sampling generates a small suction/capillary force 
(stylet capillary/slow-pull technique; SP). In contrast, greater suction/vacuum is created attaching a 5 or 
10 mL syringe to the hub of the needle after quick removal of the stylet (standard suction; SS). It is 
assumed that the aspiration of cells of hard, fibrotic cancers requires greater suction power, however in 
hypervascularized cancers the same suction force could result in increased bloodiness of smears which 
interferes with pathological evaluation. EUS elastography could help in determination of tissues 
stiffness, and based on this, in the differentiation between benign and malignant lesions, however, in 
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many medical centers elastography is not available, so the choice of sampling technique could only be 
based on the characteristics of the target organ. Pancreatic adenocarcinomas are typically hard lesions 
due to prominent desmoplastic stromal reactions. The benign lymph nodes are predominantly soft, green 
structures, the appearance of blue areas is suggestive for malignancy. Besides the stiffness, the 
vascularity of the normal parenchyma of an organ influences the bloodiness of EUS-FNA samples. Liver 
is a typically hypervascularized organ. The technical guideline of European Society of Gastrointestinal 
Endoscopy (ESGE) recommends continuous suction for EUS-FNA of pancreatic solid masses and cystic 
lesions. Recently published comparison studies are questioning this, although their results are 
contradictory. Some studies suggest that the quality of smears obtained by SP technique is better 
compared with SS, but others disprove this. Numerous prospective studies with contradictory results 
have assessed the technical aspects of pancreatic EUS-FNA sampling. On the other hand, mainly 
retrospective studies have been published about the detailed sampling methods of cancers of other 
organs, and in these cases, only lower quality evidence-based recommendations are available. 
Esophageal cancers and pancreatobiliary malignancies are often diagnosed at a locally advanced 
or metastatic stage, when curative resection is no longer feasible, and the therapeutic options are largely 
limited to the oncological treatment and palliation of symptoms. Self-expandable metal stent (SEMS) 
placement is the most common mean of palliation of dysphagia caused by esophageal cancers, and it 
could be effective for the palliation of malignant tracheoesophageal fistulas (TEF). This minimally 
invasive endoscopic procedure could rapidly improve the symptoms of patients, but in 30-50% of the 
cases minor or major complications occur with the return of dysphagia. The early recognition and 
management of complications substantially influences the efficacy of therapy. Endoscopic treatment is 
firstly recommended due to its minimal invasiveness and low burden of patients. In contrast to the high 
technical and functional success rate of the first stent implantation, endoscopic management of SEMS 
complications represents a real challenge also for experienced gastroenterologists. 
In approximately 70% of pancreatic cancers, some degree of biliary obstruction has occurred at 
the time of diagnosis, regardless of stage, and such obstruction is frequently associated with decreased 
length of survival. ERCP with placement of plastic stents (PSs) or SEMSs is the first-choice procedure 
for the palliation of malignant obstruction of the infrahilar CBD. In the traditional approach, the choice 
of stent depends on the patient’s clinical condition and the disease stage. The most important advantages 
of PSs over SEMSs are the easier insertion and favorable upfront cost; nevertheless, PSs need to be 
replaced every 3 to 4 months to prevent or manage the complications, such as occlusion and migration. 
Longer stent patency of SEMSs might compensate for its substantially higher cost. In the guidelines 
published in 2012, the ESGE recommended the use of 10-Fr PSs if the diagnosis of malignancy is not 
established or if the patient's life expectancy is less than 4 months. In contrast, the newer guidelines, 
published in 2017, highlight the priority of SEMS usage, regardless of cancer stage. Nonetheless, the 
use of PSs has not yet substantially decreased due to their costs. Cost effectiveness of stenting with 




2.1.  Comparison of diagnostic yield of EUS-FNA samples obtained by SP and SS techniques 
- To prospectively compare the diagnostic yield of EUS-FNA samples obtained by SP and SS 
in patients with suspected malignant pancreatic lesions based on the number of diagnostic 
smear pairs, bloodiness, and cellularity. 
- To prospectively compare the efficacy of SP and SS techniques of EUS-FNA in the sampling 
of pancreatic and extrapancreatic tumors. 
2.2. Assessment of efficacy, safety, and cost-effectiveness of endoscopic SEMS placement for 
palliation of upper gastrointestinal malignancies 
- To retrospectively evaluate the success and complication rate of esophageal stent 
implantation and to determine the frequency and efficacy of repeated endoscopic 
interventions related to SEMS complications. 
- To retrospectively compare the therapeutic efficacy and cost effectiveness of SEMS and PS 
in the treatment of primary malignant biliary obstruction in real-life settings.  
 
3. PATIENTS AND METHODS 
3.1. Prospective comparison of diagnostic yield of EUS-FNA samples obtained by SP and SS 
techniques 
3.1.1. Technical aspects of EUS-FNAs 
At least one puncture was performed using both SS and SP techniques with the same needle 
during approximately 7-10 back-and-forth movements done in fanning manner under continuous 
ultrasound control. In case of SP, suction force is generated by the slow pull out of stylet during the 
back-and-forth movements of the needle. In case of SS technique, 5 ml syringe was attached to the hub 
of the needle after quick removal of the stylet to create greater suction force compared to SP. The 
puncture was considered technically successful if the suction force was strong enough for mobilizing 
any grossly or microscopically identifiable cellular material from the target organ regardless of their 
diagnostic value. The obtained material from the needle was pushed on the slides with the reinsertion of 
the stylet. The coherent tissue species were removed from the glass slides and placed in 10% buffered 
formalin, smears were made from the remaining specimen and fixed in 96% methanol for at least 10 
minutes.  
3.1.2. Pathological assessment 
Pathological diagnosis was based on a combination of cytological and histological diagnosis. The 
formalin-fixed and paraffin-embedded tissues were processed using the standard protocol for 
endoscopic biopsies. All cytological smears were stained by hematoxylin-eosin; immunocytochemistry 
was performed only in selected cases on smears with high cellularity. The bloodiness and cellularity of 
smears was assessed in semiquantitative manners on a scale from 0 to 3.   
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3.1.3. Diagnostic yield of EUS-FNA samples obtained by SP and SS in patients with suspected 
malignant pancreatic lesions 
92 patients were enrolled who underwent EUS-FNA sampling due to suspected pancreatic 
cancer. The inclusion criteria were the following: 1) previously identified solid pancreatic lesions by 
cross-section imaging modalities which were suspicious for malignancy; 2) unresectable disease due to 
local invasion, dissemination to distant organs, severe comorbidity or poor general condition of the 
patient, or cases when the patient did not consent to surgery; 3) the cytological or histological 
verification of pancreatic cancer was necessary for the selection of adequate further therapy. The 
efficiency and diagnostic value of EUS-FNA sampling was determined based on the classification of 
Papanicolaou Society. The sampling was considered diagnostic if it clearly confirmed the presence of 
non-neoplastic (Papanicolaou II category) or neoplastic pancreatic lesion (Papanicolaou IV, and VI 
categories), or when the cytopathologist had a high degree of certainty of the presence of carcinoma in 
clinically unequivocally malignant-appearing tumors (Papanicolaou V category). 
3.1.4. Comparison of efficacy of SP and SS techniques of EUS-FNA in the sampling of pancreatic 
and extrapancreatic tumors 
 The inclusion criteria of patients were (i) suspected malignant solid pancreatic or 
extrapancreatic lesions identified by cross-section imaging modalities, and (ii) cytological or 
histological verification of lesions necessary for the selection of adequate further therapy. Criteria of 
exclusion from the analysis were major protocol deviation: (i) use of 25G, 19G or ProCore needles, (ii) 
application of only one of the two techniques or (iii) other sampling technique. 
The quality assessment of EUS-FNA sampling was based on the number of obtained smear 
pairs, the proportion of diagnostic smear pairs, as well as on the bloodiness and cellularity of specimens. 
Diagnostic accuracy was determined by comparing the EUS-FNA diagnosis with the final diagnosis. 
On the one hand, the final diagnosis was based on the pathological assessment of samples obtained by 
surgical resection, autopsy, or repeated sampling with another sampling modality. On the other hand, it 
was determined after more than 6-months of follow-up: malignancy was confirmed by the tumor 
progression or metastasis formation, while the lesion was considered to be benign if clinical course did 
not reveal any deterioration. 
3.1.5. Ethical approval and consent to participate 
The study protocols were approved by the Regional and Institutional Human Medical Biological 
Research Ethics Committee of the University of Szeged (clinical trial registration number: 3679 SZTE). 




3.2.  Assessment of efficacy, safety, and cost-effectiveness of endoscopic SEMS placement for the 
palliation of upper gastrointestinal malignancies 
3.2.1. Success and complication rate of esophageal stent implantation and determination of 
frequency and efficacy of repeated endoscopic interventions related to SEMS complications 
212 patients with malignant esophageal obstruction or TEF who underwent SEMS implantation 
between 2007 and 2014 were retrospectively enrolled to our study. The inclusion criteria were: 1) 
malignant esophageal obstruction or TEF confirmed by endoscopy and/or barium swallow/meal 
examination; 2) pathologically diagnosed esophageal malignancy; 3) unresectable tumor with advanced 
stage or poor surgical candidates; 4) onco-team recommended oncological treatment and/or palliative 
esophageal SEMS implantation. 
Various types of esophageal stents were used. The diameter of the applied stents’ body was 18 
or 20 mm, and the material of stents and their coating were identical in products made by the same 
manufacturers (polytetrafluoroethylene, silicone, polyurethane, etc.; nitinol, steel, etc.). The pattern 
(weave, braided, knits, etc.) and shape of stents varied widely depending on the altered anatomical 
situations. The selection of the optimal stent depended on the disease location and length of obstruction. 
In case of tumors of the upper third of the esophagus and the cardia, specific SEMS were inserted (cardia 
umbrella stent, anti-reflux valve, anti-migration property, etc.) which could reduce the risk of foreign 
body sensation in the pharynx and the severity of gastroesophageal reflux. The choice between partially 
and fully covered stents was individualized, depending on the risk of restenosis and migration: fully 
covered SEMS was preferred in case of a long and significant stenosis, in contrast to partially covered 
stents, which were applied in cases with higher migration risk. The stent was at least 2 cm longer than 
the endoscopically measured length of stenosis. The proximal and distal ends of the neoplasia were 
marked with external metal markers. If the stenosis was too tight to allow the passage of the stent 
delivery system and the endoscopic visualization of the distal part of esophagus, endoscopic balloon or 
bougie dilation was performed first.  
The efficacy of SEMS implantation was characterized by technical and functional success rate. 
The intervention was considered technically successful if the stent was opened correctly in the proper 
position confirmed by X-ray and endoscopy, and functionally successful if the oral feeding of the 
patients became possible 24 hours after the intervention. Minor complications were defined as mild-to 
moderate events related to stent implantation which could be treated conservatively without the need for 
hospitalization (gastroesophageal reflux, emesis, retrosternal pain, mild dysphagia, etc.). All patients 
received opiate pain killers, and in case of distal obstruction prophylactically proton pump inhibitor 
therapy with or without prokinetic drugs to avoid the reflux. Major complications were defined as 
severe, often life-threatening complications, which required repeated hospitalization and endoscopic 
interventions (stent migration or obstruction, aspiration pneumonia, arrhythmia, hematemesis, etc.).  
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3.2.2. Comparison of therapeutic efficacy and cost effectiveness of SEMS and PS in the treatment 
of primary malignant biliary obstruction in real-life settings. 
 
We gathered retrospective data about every patient with unresectable primary pancreatobiliary 
malignancy who underwent endoscopic stent placement for distal biliary obstruction between 2008 and 
2013. In all cases, the malignant biliary stenosis was confirmed by cross-sectional imaging and/or 
histological examination, and the tumor was unresectable based on the surgeon's opinion. In three cases, 
endoscopic biliary stenting was required because patients did not agree to surgery of resectable cancers. 
The exclusion criteria were; (1) surgical resection or biliary bypass performed less than 4 weeks after 
the first biliary stent implantation; (2) concurrent gastric outlet obstruction and malignant biliary 
obstruction at the time of stent placement; (3) hilar or intrahepatic malignant biliary obstruction 
unsuitable for endoscopic treatment. 
The efficacy of stent implantation was characterized by technical and functional success rates, 
duration of stent patency and complication rate of stenting. The intervention was considered technically 
successful if the stent was placed across the stricture in the proper position, as confirmed by radiography 
and endoscopy. Functional success of the stent was defined as restoration of bile outflow, detected by 
endoscopy immediately after drainage, and as more than 30% decrease in serum bilirubin level from 
baseline within a week after stenting. Duration of stent patency was defined as the period between the 
stent placement and either functional failure or the patient's death. Functional failure was determined by 
the return of signs of biliary obstruction: symptoms of cholangitis (icterus, pruritus, abdominal pain, 
fever) and/or elevation of liver enzymes and/or elevation of serum bilirubin level.  
During the economic analysis, we assessed only the costs of medical treatment directly 
associated with the management of biliary obstruction: the cost of stents (SEMS: 120,000 HUF; PS: 
5,500 HUF), repeated interventions (ERCP: 37,855 HUF; percutaneous transhepatic drainage: 79,086 
HUF), and hospital stay in correlation with biliary obstruction (cost of hospitalization per a day: 30,000 
HUF). Palliative surgical interventions and repeated hospitalizations were required independently from 
biliary obstruction and endoscopic stenting due to progression of pancreatobiliary malignancy.    
3.2.3. Ethical approval and consent to participate 
The study protocols were approved by the Regional and Institutional Human Medical Biological 
Research Ethics Committee of the University of Szeged (ethics approval number: 3680 SZTE). The 
study was carried out under the declaration of Helsinki. 
3.3.  Statistical analysis 
SPSS software version 22 and 24 (SPSS Inc., Chicago, Illinois, USA), SigmaPlot 12.5 (Systat 
Software Inc., San Jose, California, USA) and R statistical software version 3.4.2 (R Foundation for 
Statistical Computing, http://www.R-project.org) was used for the statistical analysis of data. The 
descriptive statistics were reported as frequencies (N), percentage (%), mean ±SD and median with 
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ranges. The differences in the quality indicators between the SS and SP group were compared using 
paired sample t-tests and Mann-Whitney Rank Sum Test. Differences in continuous variables such as 
survival time and duration of stent patency were assessed with an independent samples t test. Values of 
p<0.05 were considered significant. We used logistic regression analysis, Fisher’s exact test and Chi 
Squared test to identify the factors that can modify the effectiveness and quality indicators of sampling, 
the risk of SEMS complications and the cost-effectiveness of stenting. 
4. RESULTS 
4.1. Comparison of EUS-FNA samples obtained by SP and SS techniques 
4.1.1. Diagnostic yield of EUS-FNA samples obtained by SP and SS in patients with suspected 
malignant pancreatic lesions 
 
92 EUS-FNA samplings of 89 patients were involved. Sampling had to be repeated in three 
patients due to non-diagnostic smears. There was no significant proportional variance with regard to the 
patients’ gender. Mean age at the time of sampling was 66.1 years (range 27-95; median 69). Lesions 
were located most frequently in the pancreatic head (N=71; 79.8%). The mean diameter was 31.8 mm 
(range 7-62; median 30), and in 44 cases (47.2%) cancer antigen 19-9 (CA19-9) was elevated. There 
was no significant difference between the use of Cook Medical and Olympus EZ Shot 2 needles (47 vs. 
55 cases). The mean number of passes for each lesion was 4 (3-7; median 4). 
EUS-FNA sampling was diagnostic in 72 cases (78.3%): the presence of neoplasm was 
confirmed in 69 cases (Papanicolaou IV, V, VI) and chronic pancreatitis in 3 cases (Papanicolaou II). 
There was no significant difference between the diagnostic yield of SP and SS (65.2% vs. 67.4%), 
although the technical success rate was higher in the SS group (92.4% vs. 100%), but it was not 
statistically relevant. Cytological examination of the fluid obtained by flushing the needle with saline 
confirmed the diagnosis in 31 cases (33.7%), and in one patient the diagnosis was based only on this 
cytological sample. Histological samples were taken in 60 cases with similar efficiency in the SS and 
SP groups (50.0% vs. 53.3%). There was no detectable difference between the two groups in the 
diagnostic yield of histological samples (58.7% vs. 63.2%). The diagnostic yield of EUS-FNA 
examination was not influenced by the endosonographer, the needle type, tumor size and location. 
The average number of smear pairs for one pass was significantly higher in the SS group (3.56; 
range 1-9.5; median 3.5) compared with the SP one (1.84; range 0-7.5; median 1.5), but it was associated 
with considerably increased bloodiness (1.50 vs. 2.19; p<0.001). Cellularity did not differ statistically 
between the groups (1.58 vs. 1.37; p=0.2554). In contrast, the proportion of diagnostic smears obtained 
with SP was higher (41.8% vs. 30.0%; p=0.003). 
In 69 of 72 diagnostic EUS-FNA samplings pathological examination demonstrated neoplastic 
pancreatic lesions. Ductal adenocarcinoma was the most frequent neoplasm with 64.1% incidence rate. 
Five low grade and one high grade NETs were identified (6.5%). The latter was proved to be ductal 
adenocarcinoma by autopsy. On one occasion signet ring cell carcinoma was found. Repeated 
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histological sampling (5 autopsies, 8 surgical samples, 2 transabdominal core biopsies) confirmed the 
results of EUS-FNA in 14 cases, and in the rest 55 cases the clinical course affirmed the diagnosis. In a 
case of chronic pancreatitis based on the FNA results, Whipple procedure was performed due to biliary 
obstruction. Pathological evaluation of the surgical specimen revealed pancreatic intraepithelial 
neoplasia 1B besides chronic pancreatitis. In 5 out of 14 non-diagnostic EUS-FNAs (Papanicolaou I) 
benign disease was detected by further examinations (1 autoimmune and 3 chronic pancreatitis: 1 
infection). In the rest 9 cases ductal adenocarcinoma (N=5), biliary duct carcinoma (N=1), IPMN (N=1) 
and metastatic renal cell carcinoma (N=2) were identified. In the background of atypia benign disorder 
was found only in one case (autoimmune pancreatitis).  
 
4.1.2. Comparison of efficacy of SP and SS techniques of EUS-FNA in the sampling of pancreatic 
and extrapancreatic tumors 
 
201 patients were prospectively enrolled and analyzed in the study from which 145 patients 
were categorized into pancreatic tumors and 56 patients (46 lymph nodes and 10 liver lesions) into 
extrapancreatic tumors subgroup. The male-female ratio was 85:116. Mean age at time of sampling was 
65.13 years (range 19-94; median 67).  
The EZ Shot 2 needle was significantly more frequently used compared with Echotip needle 
(153 vs. 48; p<0.001), and statistically significant proportional variance regarding examiner was 
observed (169 vs. 32; p<0.001). However, there was no substantial difference between the subgroups in 
terms of patients’ gender and age, the investigator of EUS-FNA and the type of used needle. 
An average 3.19 (range 2-7; median 4) punctures were performed during EUS-FNA 
examinations in which the proportion of the usage of SS and SP techniques was almost equal (1.98 
[range 1-4; median 2] vs. 1.94 [range 1-5; median 2]). The overall technical success rate of EUS-FNA 
was 100%. The diagnostic accuracy independently from sampling technique was 88.28% in pancreatic 
cancers and 75.00% in the extrapancreatic tumors subgroup with high sensitivity, specificity, and 
positive predictive value. In 42 cases (20.90%), the diagnosis was based on the pathological evaluation 
of cytological samples only, however, in the remaining 159 cases (79.10%) appropriate histological and 
cytological samples were obtained. The final diagnosis was benign only in 24 cases (11.94%). EUS-
FNA examination confirmed the presence of malignant disorder in 90.34% of cases in the pancreatic 
cancer subgroup and in 82.14% of cases in the extrapancreatic cancer subgroup. 
The technical success rate of the sampling techniques was equally high in cases of pancreatic 
cancers and extrapancreatic tumors. In the pancreatic cancers subgroup, no significant difference was 
observed in terms of diagnostic accuracy, sensitivity and specificity of sampling, as well as the rate and 
diagnostic value of obtained histological samples. In contrast, in the extrapancreatic tumors subgroup, 
the SS technique achieved substantially lower diagnostic accuracy, however, the characteristics of 















Technical success rate 134 (92.41%) 142 (97.93%) 0.788 52 (92.86%) 56 (100%) 0.869 
Mean number of 
smears per puncture 
1.74±1.09  
(0-8; med. 1.5) 
3.19±1.82 
(0-10; med. 3) 
<0.001 
1.62±1.11 
(0-6; med. 1) 
3.28±1.19 




46.69% 36.33% 0.002 49.17% 30.67% <0.001 
Histological samples 
obtained 
96 (66.21%) 94 (64.83%) 0.623 44 (78.57%) 45 (80.36%) 0.999 
Diagnostic yield of 
histological samples 
73 (76.04%) 73 (77.66%) 0.999 32 (72.72%) 31 (68.89%) 0.999 














Sensitivity 81.06% 83.33% 88.64% 68.10% 54.17% 72.34% 
Specificity 84.62% 84.62% 84.62% 88.89% 100% 88.89% 
NPV 31.43% 33.33% 42.31% 34.78% 26.67% 38.10% 
PPV 98.17% 98.21% 98.32% 96.97% 100% 97.14% 
Accuracy 81.38% 83.45% 88.28% 71.41% 60.71% 75.00% 
2. Table: No significant difference could be observed in terms of diagnostic accuracy of EUS-FNA sampling using slow-pull 
and standard suction techniques in pancreatic and extrapancreatic tumors.  
The diagnostic accuracy (69.70% vs. 79.41%; p=0.699), the technical success rate (100% vs. 
98.24%; p=0.998) and quality of samples obtained by SS technique (cellularity: 1.09±1.10 vs. 
1.14±1.10, p=0.811; bloodiness: 2.00±0.90 vs. 2.07±0.85, p=0.678; mean number of smear pairs: 
3.21±1.78 vs. 3.21±1.95, p=0.994; proportion of diagnostic smears: 32.45% vs. 35.38%, p=0.666) did 
not differ significantly between the EUS-FNA examiners. In contrast, substantial examiner-dependency 
was observed in terms of technical success rate of sampling (81.82% vs. 97.06%; p<0.001) and the 
quality of smears using SP techniques of FNA (cellularity: 1.03±1.26 vs. 1.48±1.20, p=0.061; 
bloodiness: 1.12±0.89 vs. 1.57±0.84, p=0.011; mean number of smear pairs: 0.98±0.71 vs. 1.85±1.10, 
p<0.001; proportion of diagnostic smears: 43.31% vs. 48.00%, p=0.597) without any decrease in 
diagnostic accuracy (63.64% vs. 78.82%; p=0.099). In cases of pancreatic and extrapancreatic cancers, 
the subgroup analysis revealed almost similar difference between the EUS-FNA examiners using SS 
technique. The type of needle did not influence the characteristics of EUS-FNA samples obtained by SP 
and SS techniques. 
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The SS technique resulted in significantly higher number of smear pairs for one pass in both 
pancreatic and extrapancreatic tumors, but at the same time it was associated with considerably 
increased bloodiness and the proportion of diagnostic smear pairs decreased. The type of suction did not 
influence the cellularity of smears in the pancreatic cancers subgroup, however in cases of 
extrapancreatic tumors the increased blood contamination covered the tumor cells, thereby resulted in 
reduced cellularity.  
 
1. Figure: Quality assessment of specimens based on the cellularity and bloodiness of smears. 
 
2. Figure: Quality assessment of sampling based on the mean number of smears pair punctures and the proportion of 
diagnostic smear pairs. 
Mild early complications in correlation with EUS-FNA sampling occurred in five cases 
(2.49%). In the pancreatic tumor subgroup, four patients (2.76%) had threefold elevation in serum 
amylase level 24-hours after sampling, which did not cause clinical symptoms in three cases. In one 
case (1.56%) of an extrapancreatic tumor EUS-FNA, mild peritonitis occurred after liver sampling of a 





4.2.  Assessment of efficacy, safety, and cost-effectiveness of endoscopic SEMS placement for 
palliation of upper gastrointestinal malignancies 
5.3.1 Success and complication rate of esophageal stent implantation and determination of 
frequency and efficacy of repeated endoscopic interventions related to SEMS complications 
 
In the 212 enrolled cases 238 SEMS implantations were performed due to malignant esophageal 
obstructions caused by predominantly primary esophageal tumors (83.49%) or lung cancers (13.68%). 
In 33 cases TEF was present at the time of SEMS implantation.  
The technical success rate of the first SEMS implantations was 99.06%. In two cases the cardia 
stent spontaneously migrated into the stomach immediately after the implantation and reposition was 
not feasible. In one case intolerable retrosternal pain and severe dyspnea and in three cases development 
of severe complications (arrhythmia, pneumonia) hampered the oral feeding of patients, therefore the 
functional success rate decreased to 97.64%. Procedure related death was 1.26%: two patients died due 
to malignant supraventricular arrhythmia and aspiration pneumonia less than 24 hours after stent 
implantation. In total, major and minor complications were observed in 84 of 212 (39.6%) patients. 
Retrosternal pain (13.68%) and stent migration (6.57%) were the most frequent early complications, and 
they appeared less than 4 weeks after SEMS implantation. Fatal complications were seen in three cases. 
One patient died 24 hours after stent implantation due to aspiration pneumonia, respiratory insufficiency, 
and septic shock. In two cases malignant supraventricular tachycardia occurred with cardiovascular 
instability immediately after stenting. These patients died despite their admission to intensive care unit 
and the removal of the stent. After the 4-week follow-up stent obstruction caused by tumor overgrowth 
or ingrowth (15.09%), migration (10.38%) and new TEF formation (7.08%) were the most common 
complications. No correlation was found between clinical/procedural factors (gender, age, tumor type, 
location, necessity of dilation during stenting, coverage of SEMS, and presence of TEF at the time of 
stenting) and the development of complications. 
In 55 cases (25.94%) repeated endoscopic interventions were required.  In 16 patients the first re-
intervention was performed 24-48 hours after stent implantation; it was necessary due to early stent 
migration (12 cases), supraventricular arrhythmia (2 cases), dyspnea (one case) and intolerable 
retrosternal pain (one case). In this group, multiple endoscopies were required in every second patient 
during the follow-up. In case of patients with an uncomplicated early post-implantation period (24-48 
hours), 1.98 (range 1-6; median 2) re-interventions were performed per patient from which the first took 
place at an average of 13.58 weeks (range 1.5-48; median 11) after stenting. Stent re-implantation 
occurred in 23 cases: 21 patients received two, one patient three and one patient four SEMSs due to stent 
migration (7 cases), occlusion (10 cases) or new TEF formation (8 cases). Endoscopic removal of the 
stent due to complications (arrhythmia, retrosternal pain, migration) was unavoidable in 7 cases. In 48 
of 55 patients (87.27%) oral feeding was resolved by an endoscopic procedure, in 6 cases transient 
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parenteral or permanent enteral feeding with gastric tube or percutaneous endoscopic gastrostomy (PEG) 
was feasible. 
 
3. Figure: Repeated endoscopic interventions after esophageal stent implantation. 
No statistically significant correlation was found between clinical/procedural factors (gender, age, 
tumor type, location, necessity of dilation during stenting, coverage and manufacturer of SEMS, and 
presence of TEF at the time of stenting) and the necessity of repeated endoscopic interventions. 
 
4.2.1. Comparison of therapeutic efficacy and cost effectiveness of SEMS and PS in the treatment 
of primary malignant biliary obstruction in real-life settings. 
Of the 74 patients with primary malignant biliary obstruction, 37 were in the PS subgroup and 
37 were in the SEMS subgroup. The male-female ratio was 40:34. Mean age at time of sampling was 
67.64 years (range 25-94; median 68). The biliary obstruction was caused by pancreatic cancer in 46 
cases (61.62%), by primary biliary duct cancer in 13 cases (17.57%) and by ampullary cancer in 5 cases 
(6.76%). In the rest 10 cases (13.51%), the bile duct was compressed by metastases of other organs. The 
clinical characteristics of patients (gender, age) and neoplasms (type of primary tumor, location of 
obstruction, rate of distant metastasis, and use of chemoradiotherapy) did not differ significantly.  
 SEMS PS p VALUE 
Technical success rate (%) 100 97.29  
Functional success rate (%) 94.59 86.49  
Average stent patency (week) 19.11 8.29 0.0041 
Complication rate (%) 37.84 56.76 0.16 
Number of hospitalizations 1.18 2.32 0.05 
Length of hospitalization (day) 10.89 13.7 0.19 
Repeated interventions (patient) 17 27 0.033 
3. Table: Comparison of clinical characteristics of SEMS and PS implantation. 
The rates of technical success and functional success of SEMSs and PSs were similarly high 
and independent of stent type. Functional failure occurred in 2 cases in SEMS group (5.41%), while it 
20 
 
occurred in 5 cases in PS subgroup (13.51%). Stent-related death was very low (0.014%): only one 
patient died of cholangiosepsis less than one week after ERCP. The complication rate of SEMS was 
lower compared with plastic stents, but it was not significantly different. Stent occlusion was the most 
frequent complication. The mean follow-up time for patients was 23.41 weeks (range 1-86, median 16). 
Data of 31 patients in the PS and 28 patients in the SEMS subgroup were assessed during the stent 
patency analysis. The mean time of stent patency were significantly higher in the SEMS. 
In the SEMS group the frequency of re-hospitalization of patients in context with stent 
complications were substantially lower, but the necessity of reintervention for stent dysfunction was 
higher, in contrast, the length of hospitalization did not differed significantly between the groups. In the 
plastic stent group, the multiple stent implantation increased the stent patency: the second stent raised it 
from 7.68 to 10.75 weeks.  
In 78.30% of cases the stent complications were manageable endoscopically in both groups: re-
ERCP, re-stent implantation or stent replacement were performed. Percutaneous biliary drainage was 
required in four cases in both subgroups; however, surgical intervention was performed more frequently 
in the PS subgroup (13 cases vs. 2 cases). 
In the SEMS subgroup, uncovered metal stent was inserted in 23 (62.16%), partially covered 
and covered stent were used in 8 (21.62%) cases and in 5 (13.51%) cases, respectively. In the PS 
subgroup, an average of 1.32 stent implantation were performed during the first ERCP examination: in 
26 cases only one, while in 10 cases two and in one case three PSs were inserted simultaneously. 
Similarly, an average of 1.38 PS was placed during the repeated endoscopic interventions. Duration of 
stent patency was increased by implantation of multiple stents in comparison with the use of single stents 
(10.75 weeks vs. 7.68 weeks, p<0.05). 
There was no difference in the total cost of treatment of malignant biliary obstruction between 
the two groups (SEMS: 499,329 HUF vs. PS: 512,793 HUF, p=0.848; difference per patient: 13,464 
HUF). If the patients’ survival time was more than two months, the cost-effectiveness of SEMS was 
better than PSs.  
5. DISCUSSION 
Our prospective studies simultaneously evaluated the efficiency of EUS-FNA using SP and SS 
techniques in which the differences between the methods were determined not only on the basis of 
diagnostic accuracy, but also considered the quality indicators of obtained smears and the acquisition of 
core tissues. The most important advantage of our two studies is the separate assessment and comparison 
of the diagnostic accuracy of EUS-FNA in the sampling of organs with different characteristics, but the 
sampling efficacy of the two techniques was assessed in the same lesions; therefore there was no 
difference in the tumor characteristics (size, location, vascularity, stiffness) and in the diagnostic process 
(premedication, endoscope, needle type and diameter, endosonographer, assistant, pathologist, etc.). 
Although, there are some limitations to our researches. These are single-center cohort studies with 
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participation of two different investigators, in which relatively small number of cases were enrolled. Not 
being a randomized controlled trial is another drawback of our study. The study protocol exactly defined 
the proper execution of SP and SS techniques, but did not determine the order of sampling methods, it 
was based on the preference of investigator. Furthermore, the pathologists involved in smears evaluation 
were not blinded to the sampling technique. 
Similarly to our results, most of the recently published studies did not find significant difference 
between the SP and SS techniques in terms of diagnostic accuracy in case of pancreatic cancer, however 
they suggested that the lower suction force of SP with 22G needle could improve the quality of smears, 
which is manifested in a higher proportion of tissue microfragments, greater cellularity of smears and 
lower blood contamination. In contrast, Puri et al. reported significantly higher sensitivity and negative 
predictive value when suction technique was applied (85.7% vs. 66.7%), but it was also associated with 
increased number of slides (17.8±7.1 vs. 10.2±5.5; p=0.001) and higher blood-contamination. 
Prospective study of Lee et al. contradicted this, because significantly superior diagnostic accuracy was 
detected when SP with fanning technique was applied compared with SS (88% vs 71%, p=0.044). Nakai 
et al. found a difference between SP and SS technique only when 25G needle was used (90% vs. 67%). 
Efficiency of four types of suction (slow-pull technique, suction techniques with 5-ml/10-ml/20-ml 
syringes) was assessed in the retrospective study of Chen et al. in which significant differences between 
the groups was observed in terms of cytological diagnostic accuracy (90.3% vs. 63.2% vs. 58.8% vs. 
55.6%, p=0.019), sensitivity (88.2% vs. 41.7% vs. 40.0% vs. 36.4%, p=0.009) and blood contamination 
(score ≥ 2 for 29.0% vs. 52.6% vs. 70.6% vs 72.2%, p=0.003). 
Our study also confirmed that the diagnostic accuracy and sensitivity of sampling did not differ 
significantly in case of pancreatic cancers between the SP and SS techniques, however substantial 
decrease was observed in extrapancreatic cancers (such as lymph node and liver cancers) when SS 
technique were used. Although the optimal sampling technique for pancreatic EUS-FNA has been 
examined in several studies, only few clinical trials dealt with the technical aspects of other organs' 
sampling. Wallace et al. analyzed the results of 42 EUS-FNAs in patients with lymphadenopathy and 
concluded that SS technique was associated with an increase in the cellularity, but it worsens the 
specimen’s bloodiness compared with FNA without suction, therefore, it does not improve the 
likelihood of obtaining a correct diagnosis (OR 1.52: 95% CI [0.81, 2.85]). The randomized controlled 
trial of Bansal et al. assessed the results of 300 EUS-FNA examinations of 235 lymph nodes and 65 
pancreatic masses, and found that significantly more slides and blood clots were generated by the suction 
method compared with the capillary action and no suction subgroup. The diagnostic accuracy was 
similarly high in both groups (91%, 91% and 94%, p=0.67) but contrary with our results, the efficiency 
of FNA sampling of lymph nodes and pancreatic cancers did not differ significantly when SP or SS 
technique were used. 
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The EUS-FNA using conventional needles could obtain not only cytological, but also 
histological specimens. Multiple immunostainings of core tissues are often essential for the accurate 
diagnosis of nonmalignant lesions and for precise subtyping of uncommon neoplasms or metastases. In 
our studies, the acquisition of tissue microfragments showed similar proportion in pancreatic and 
extrapancreatic cancers subgroups using both SP and SS techniques. Our findings correlate with the 
results of other prospective studies. Kida et al. achieved 83% tissue sampling rate for histology with a 
diagnostic accuracy of 85%. Despite the significantly higher sampling rate for cytology, they found no 
significant difference between the diagnostic accuracy of histology and cytology using 22G FNA needle 
(66% and 75%). Park et al. found that combined analysis is more sensitive than cytology and histology 
alone (81.8% vs. 69.8% vs. 67.2%; p<0.01). Wang et al. assessed the correlation between suction power 
of FNA and diagnostic yield of core tissues and concluded that the samples that were obtained for 
histopathological diagnosis using 5 ml suction were superior to those obtained using SP technique or 10 
ml suction. Hucl et al. showed that the average number of passes to obtain sufficient tissue was 
significantly lower when 22G ProCore needles were used compared with the standard 22G needles 
(1.2±0.5 vs. 2.5±0.9; <0.001), but the diagnostic accuracy did not show relevant difference in the two 
groups. Vanbiervliet et al. confirmed these results, and additionally found that the overall sample quality 
was significantly better in case of standard 22G needle. 
Our retrospective observational study of 212 patients has confirmed that esophageal stent 
implantation is easy to perform, and a safe and effective treatment in neoplastic esophageal obstruction 
and malignant TEF. The role of SEMS placement in the palliative treatment of malignant esophageal 
stenosis is unquestionable because it provides immediate and potentially long-lasting relief of 
obstructive symptoms. However, previous studies shown that the rate of SEMS-related adverse events 
is high, and varies between 22-50% depending on the location of the tumor, the presence of a fistula or 
tumor shelf, concomitant chemo-irradiation, tumor vascularity and the stent design. Stenting of upper 
esophageal tumors represents a real therapeutic challenge due to pain and globus sensation, an elevated 
risk of TEF and aspiration pneumonia. In this location the use of a specially designed stent is 
recommended the proximal end of which keeps a 2-cm distance from the upper esophageal sphincter 
after stenting. A retrospective study has analyzed clinical data of 104 patients with malignant proximal 
esophageal stenosis and concluded that SEMS placement is safe and effective, and the complication rate 
is not elevated compared to stenting in the distal esophagus. The use of newly designed esophageal 
stents could reduce certain type of complications such as SEMS with antireflux valve or antimigration 
property, cardia umbrella stents. Results of previous studies have shown better long-term efficacy in 
case of partially or fully covered stent placement compared to uncovered. The appropriate use of specific 
designed stents could help to prevent the development of short- and long-term adverse events. In our 
study fully covered SEMSs were applied most frequently (partially covered 16.39% vs. fully covered 
83.11%), and in every cardia or proximal esophageal tumor specially designed stents were inserted. We 
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have noted complications in 84 cases (39.62%) which showed no correlation with tumor type, location, 
necessity of dilation during stenting, coverage of SEMS and presence of TEF at the time of stenting. 
The difference between the risk factors of complications in the published data and our study might be 
caused by the retrospective study design or the relatively small number of adverse events, although it 
could also suggest that our stent choice was adequate. 
Our results revealed that the majority of SEMS complications could be successfully managed 
by endoscopic interventions (stent re-implantation, dilation of stenosis, stent reposition). Homann et al. 
analyzed clinical data of 133 patients with unresectable esophageal cancer. They found that delayed 
complications occurred in 53.4% (71 of 133 patients), these patients were successfully treated by 
dilatation (24%), placement of a second/third stent (27%), laser therapy (16%), and/or placement of a 
feeding tube (19%). Patients with repeated endoscopic interventions had a significantly longer life 
expectancy (222±26 days vs. 86±14 days, p<0.001). Recurrent dysphagia occurred in one-third of 
patients due to tumor over- or ingrowth via the stent, non-cancerous granulomatous tissue overgrowth 
or food impaction. In case of stent obstruction, either endoscopic reposition, argon plasma coagulation, 
exchange for a new stent or the second SEMS implantation could be effective to restore the esophageal 
patency. Incidence of stent migration ranges from 4 to 36%. This could be asymptomatic or manifest, 
presenting as chest pain, recurrent dysphagia, or dyspnea. Stent reposition or removal of the stent with 
a new stent implantation are the effective endoscopic therapeutic options in these cases. In our study in 
48 of 55 patients (87.27%) with SEMS-related complications oral feeding was solved by endoscopic 
interventions (dilation, reposition, re-stent implantation, stent removal).  
In most cases TEF develops next to the proximal or distal end of the stent due to the radial force 
and resulting pressure necrosis. The study performed by Shin et al. highlighted that the SEMS placement 
is clinically successful in 80% of patients with TEF, but during the follow up, recurrence of fistula was 
experienced in one third of the cases. We have found that the risk of fistula formation is high in patients 
with TEF at the time of stenting. In 8 of 11 cases (72.73%) of new TEF formation endoscopic reposition 
and/or a second SEMS placement solved the oral feeding of patients. Retrosternal pain often occurs after 
stent implantation, but it is mild to moderate in most of the cases and could be managed with opiate 
analgesics. The frequency of this minor complication varies widely among different studies from 13% 
to 60%. Our results correlate with the results of other studies: 29 patients (13.68%) experienced 
retrosternal pain, but only two of them required endoscopic intervention, stent removal (6.89%). 
Our retrospective study comparing efficacy and cost-effectiveness of plastic and metal biliary 
stents found that the duration of patency of SEMSs was almost twice that of PSs, which is consistent 
with the results of previously published clinical trials. In a 2016 meta-analysis, Moole et al evaluated 
the data of 984 patients from four retrospective and seven randomized controlled trials and demonstrated 
that duration of patency of SEMSs (median, 167.7 days; 95% confidence interval [CI], 159.2 to 176.3) 
was superior to that of PS (median, 73.3 days; 95% CI, 69.8 to 76.9), and that SEMSs had lower rates 
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of occlusion (odds ratio [OR], 0.48; 95% CI, 0.34 to 0.67) and reintervention (OR, 1.1; 95% CI, 0.9 to 
1.3) than did PSs (OR, 1.7; 95% CI, 1.5 to 1.9). Pooled analysis of randomized controlled trials did not 
reveal differences between PS and SEMS in overall patient survival (weighted mean difference, 0.67 
months; 95% CI, -0.66 to 1.99) or in the 30-day mortality odds ratio (0.80; 95% CI, 0.52 to 1.24), but 
the rate of symptom-free survival at 6 months was higher (OR, 5.96; 95% CI, 1.71 to 20.81]).  
The early clinical trials and meta-analyses suggested that SEMS placement is the right choice 
for cost-effectiveness considerations only if a patient’s life expectancy is more than 4 months. According 
to the previous ESGE guideline published in 2012, the initial insertion of a 10-Fr PSs was recommended 
if the diagnosis of malignancy was not established or if expected survival was shorter than 4 months. In 
contrast, more recent trials have demonstrated that the total cost of PS and SEMS per patient did not 
differ among patients with short (3-month) survival or metastatic disease despite the fact that SEMS 
placement was initially more expensive. Furthermore, the general and disease-specific health-related 
quality of life of patients with inoperable malignant extrahepatic bile duct obstruction was better over 
time with SEMSs than with PSs. In addition, a German retrospective study of the management of SEMS 
occlusion did not reveal significant differences in median overall duration of secondary stent patency 
(88 days for sSEMS, 143 days for PS; p = 0.069), median subsequent intervention rate (53.4% for 
sSEMS, 40.0% for PS; p = 0.501), or median case costs (5145€ for sSEMS, 3473€ for PS; p = 0.803). 
In view of new evidence, the ESGE (in the guideline published in 2017) now recommends 
SEMS insertion for palliative drainage of malignant extrahepatic biliary obstruction, regardless of the 
patient's life expectancy. The results of our study confirmed that use of PS is not superior to that of 
SEMS with regard to the cumulative cost of treatment even in cases of short (≤ 2 month) survival, but 
the total hospitalization time is longer, and the reintervention rate is higher. The most appropriate SEMS 
type in the management of malignant distal biliary obstruction is still debated. Meta-analyses have 
revealed no significant difference between covered and uncovered metal stents with regard to the 
survival benefit, overall rate of adverse events, rate of stent dysfunction, and duration of primary stent 
patency during the period from primary stent insertion to primary stent dysfunction or patient death. 
Some studies, however, have suggested that the covered SEMS is associated with a lower risk of tumor 
ingrowth but higher risks of tumor overgrowth, sludge formation, stent migration, and post-stenting 
cholecystitis. In our cohort, the coverage of stent did not influence the technical and functional success 
rate, stent patency, complication rate, or cost-effectiveness of stenting. 
6. CONCLUSION 
Our two prospective comparison studies of EUS-FNA techniques revealed that SP is an effective 
method with an outstanding technical success rate and efficacy compared to SS, furthermore, the low 
negative pressure suction generated by SP technique yields better quality smears independently from 
tumor consistency. Cellularity of smears and the rate of acquiring sufficient histological material are 
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similar with SS; however, lower bloodiness of samples and decreased number of slide pairs may result 
in faster pathological diagnosis and more cost-effectiveness in case of SP. In addition, the higher 
negative pressure suction of SS technique reduces the diagnostic accuracy of sampling in extrapancreatic 
cancers, therefore, we recommend the SP technique as the first method in the EUS-FNA sampling of 
soft tissues, such as lymph nodes and liver cancers. In case of solid pancreatic cancers, SP may be the 
optimal first choice which could be supplemented by SS technique in case no histological sample could 
be obtained or when the macroscopic appearance of the smears suggests their inappropriateness for the 
diagnosis. However, the examiner-dependency of SP technique should also be taken into account. On 
the other hand, this can also be a favorable feature, as investigators who gained a certain amount of 
experience using SP technique could achieve outstanding diagnostic accuracy. However, important 
advantage of SS technique is that it can compensate the differences between the investigators. 
Our retrospective study assessing risk factors of complications and efficacy of repeated 
endoscopic interventions after esophageal SEMS implantation found that in one quarter of patients we 
must reckon with development of complications. Despite the simplicity and high success rate of SEMS 
implantation, the treatment of SEMS-related complications represents the real clinical challenge. Our 
study has not identified any clinical factors which could help the selection of high-risk patients. 
Nonetheless, we consider that the individualized stent choice could help to reduce the frequency of 
adverse events and make repeated endoscopic interventions easier. We recommend endoscopic 
interventions as the first-line treatment for SEMS-related complications, because in most of the cases 
they make oral feeding possible. Our recommendations for the stent selection may decrease the burden 
of patients and could also make the treatment of stent complications more cost effective because they 
may reduce the frequency of stent-related complications, the number of repeated endoscopic 
interventions and the necessity of stent re-implantation. 
Our retrospective cohort study comparing the cost effectiveness of SEMS and PS placement 
confirmed that SEMS is a better choice than PS in the management of unresectable primary malignant 
biliary obstruction not only in terms of effectiveness and longer stent patency but also in terms of cost-
effectiveness. Because we found no difference in the cumulative treatment costs of patients, we 
recommend SEMS implantation regardless of patients’ life expectancy. Our results also confirmed that 
multiple stent implantation and larger stent diameter increased the duration of stent patency and 
decreased the reintervention rate, in comparison with the use of single 7-Fr stents. Therefore, if SEMS 
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